21 results about "Benign disease" patented technology

The invention provides a methylation marker for detecting liver cancer and application of the methylation marker, and relates to the technical field of biomedicine. The invention provides a methylation marker combination for detecting liver cancer of each stage, the methylation marker combination comprises one or any more of BEST4 sequences of BEST4 genes or genomes, SFMBT2 sequences of SFMBT2 genes or genomes and SPAG6 sequences of SPAG6 genes or genomes, and the combination can accurately distinguish healthy people or patients with liver benign diseases from liver cancer patients and can be used for detecting the liver cancer of each stage. Moreover, early discovery and early treatment of the liver cancer can be realized, and a new direction and possibility are provided for early diagnosis and individualized treatment of the liver cancer. According to the invention, modeling is carried out by using a method based on machine learning, three different liver cancer diagnosis models are constructed, and the models are rapid in diagnosis, can realize in-vitro noninvasive, high-sensitivity and high-specificity diagnosis, and are suitable for wide popularization.

The present invention discloses an application of a reagent for detecting the methylation level of molecular markers in the preparation of a reagent product for detecting primary hepatocellular carcinoma, belonging to the technical field of gene detection. This solution can identify whether the patient from whom the sample is derived is a patient with primary hepatocellular carcinoma by detecting the methylation level of CpG sites in the region of chr17: 30970241-30970741. If the target sample is from a patient with primary hepatocellular carcinoma, the CpG sites in the above region are at a high methylation level; if the target sample is from a healthy person or a patient with a benign liver disease (such as cirrhosis, hepatitis, etc.), the CpG sites in the above region are at a low methylation level. The CpG sites in this region can be used to distinguish between samples from patients with primary hepatocellular carcinoma and samples from healthy people, as well as between samples from patients with primary hepatocellular carcinoma and samples from patients with benign diseases (such as cirrhosis, hepatitis, etc.).

Antisense polynucleotides and their use in pharmaceutical compositions to induce exon skipping in targeted exons of the gamma sarcoglycan gene are provided, along with methods of preventing or treating dystrophic diseases such as Limb-Girdle Muscular Dystrophy.

The invention belongs to the field of pancreatic duct adenocarcinoma prediction, and provides a pancreatic duct adenocarcinoma prediction method and system based on oral flora. The pancreatic ductal adenocarcinoma prediction method based on oral flora comprises the following steps: acquiring relative abundance information of each biomarker in a potential biomarker set for diagnosing pancreatic ductal adenocarcinoma of a to-be-detected person; using the relative abundance information of each biomarker in the biomarker set and a pre-trained multivariate statistical model to obtain a probability value of suffering from pancreatic ductal adenocarcinoma; the method comprises the following steps: performing microbiome difference analysis on saliva, duodenal juice and pancreatic tissue samples of a pancreatic ductal adenocarcinoma patient group and a pancreatic benign disease patient group, and taking an intersection of differential bacteria in the samples to obtain a potential biomarker set for diagnosing the pancreatic ductal adenocarcinoma.

This invention provides a combination of bile protein biomarkers for predicting liver metastasis of pancreatic cancer and its application. The combination of bile protein biomarkers includes at least MMP9, PRTN3, and S100A12. This application transforms bile, previously considered biological waste, into a high-value diagnostic sample. Based on the differences in bile proteins among patients with benign disease, patients with pancreatic cancer without liver metastasis, and patients with pancreatic cancer with liver metastasis, four optimal biomarker combinations are screened for the first time to establish a method for predicting the risk of pancreatic cancer liver metastasis for early preoperative assessment of pancreatic cancer liver metastasis risk.

The invention provides a metabolic marker composition for distinguishing benign thyroid diseases from thyroid cancer and application of the metabolic marker composition. Based on blood metabonomics data, a diagnosis model capable of accurately distinguishing benign thyroid diseases and thyroid cancer is constructed by screening a specific metabolic marker combination and combining a machine learning algorithm, and the model has relatively high sensitivity and specificity. Based on the constructed diagnosis model, whether the patient suffers from the thyroid cancer or the benign thyroid disease can be judged at the same time only through one-time detection, excessive examination of the patient suffering from the benign thyroid disease can be avoided, excessive diagnosis and treatment are reduced, and excessive panic of the patient is avoided. The thyroid cancer diagnosis model method provided by the invention has the advantages of convenience, economy and convenience in sample acquisition, and is more suitable for large-scale population screening and regular tracking in regions with shortage of medical resources.

The invention provides a urine metabolism marker combination for distinguishing kidney benign diseases and kidney cancer and application of the urine metabolism marker combination, and belongs to the technical field of biomarkers. The urine metabolism marker combination for distinguishing the kidney benign disease from the kidney cancer comprises at least two of the following components: (S)-2-piperidine-6-carboxylic acid, 2 '-deoxyguanosine, 3-hydroxybutyric acid, 6-aminocaproic acid, glycyl-L-proline, glycyl-gamma-aminobutyric acid, L-cysteine sulfinic acid and N, N-dimethyl formamide. The amino acid sequence is shown in the specification, and the amino acid sequence is shown in the specification. The amino acid sequence is shown in the specification, namely, N, N-dimethyl glycine, N-acetyl-L-glutamic acid, L-methionine-L-aspartic acid, 2-oxoglutaric acid and glycine chenodeoxycholic acid. Model construction and verification analysis show that the AUC values of diagnosis models constructed by combining different quantities of metabolite markers are all greater than 0.8, the sensitivity is greater than 0.7, and the specificity is greater than 0.7. Therefore, based on the urine metabolism marker combination screened by the invention, the kidney benign disease and the kidney cancer can be efficiently and accurately distinguished.

The invention provides a biomolecular marker and system for diagnosing non-small cell lung cancer and application of the biomolecular marker and system, and belongs to the field of biomedicine. Related samples of non-small cell lung cancer patients, populations with lung benign diseases and healthy populations are analyzed through proteomics, and eight biomarkers capable of predicting whether a detected object suffers from the non-small cell lung cancer or not are found; combining the new markers, and further screening to obtain a combination which has the most accurate prediction result and contains five biomarkers; then, on the basis of the marker combination, a machine learning method is used for developing an optimization model formula, and the disease risk of a predicted patient is obtained through calculation, so that the non-small cell lung cancer is conveniently and efficiently diagnosed, a golden window period of intervention is mastered for high-risk people, the economic burden is relieved for low-risk patients, and clinical requirements are met.

The application provides a traditional Chinese medicine external application composition for treating benign breast disease and preparation and application thereof, and belongs to the technical field of traditional Chinese medicine compositions, and is used for solving the problems of slow effect, large side effect and poor compliance of existing drugs for treating benign breast disease. The composition is composed of Tribulus terrestris 8-12 parts, Taraxacum officinale 8-12 parts, Pheretima 2-4 parts, Cornu Cervi 8-12 parts, mirabilite 16-24 parts, Pericarpium Citri Reticulatae Viride 10-14 parts, Swertia 8-12 parts, Ophiocordyceps sinensis 2-4 parts and borneol 1-3 parts. The medicinal materials are prepared into an external application powder, and the breast part is externally applied before sleep, and the application time is more than 6 hours each time. The application adopts external use and transdermal administration, has fast effect, no digestive tract stimulation and liver and kidney burden, is convenient to use, has high compliance, and is clinically verified to have exact curative effect on mastalgia, breast hyperplasia and benign breast nodules (including BI-RADS 3 and 4a nodules), has high safety, and is suitable for long-term conditioning of benign breast disease.

The invention provides a novel combined marker for multi-target esophageal cancer detection and application thereof. A series of novel methylation sites capable of efficiently distinguishing esophageal cancer and esophagitis patients are found from high-depth whole genome methylation (WGBS) sequencing of cfDNA samples of esophageal cancer tissues, para-carcinoma tissues and normal people and targeted methylation sequencing data of cfDNA samples of esophageal cancer patients, normal people and benign disease patients; the kit can be used for efficient detection of esophageal cancer; the novel gene methylation site is combined with other esophageal cancer protein detection markers (such as CA199, CEA and SCCA), the AUC value can be further increased, and the sensitivity and specificity of esophageal cancer screening are improved.

The invention relates to a traditional Chinese medicine composition for postoperative wound recovery of anorectal benign disease as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 20-30 parts of radix sophorae flavescentis, 20-30 parts of cortex phellodendri, 10-20 parts of mirabilite, 20-30 parts of gallnut, 20-30 parts of cortex dictamni, 20-30 parts of fructus kochiae, 25-35 parts of dandelion, 1-10 parts of borneol, 20-30 parts of fructus cnidii, 25-35 parts of rhizoma smilacis glabrae, 10-20 parts of zaocys dhumnade, 25-35 parts of polygonum cuspidatum, 10-20 parts of alum, 10-20 parts of rhizoma bletillae and 10-20 parts of radix saposhnikoviae. The traditional Chinese medicine composition is applied to postoperative wound surface nursing of anorectal benign diseases such as internal hemorrhoids, external hemorrhoids, mixed hemorrhoids, anal fistula, perianal abscess and anal fissure, achieves postoperative wound surface anti-inflammation, detumescence and tissue regeneration and repair through a standardized external application mode of fumigation and hip bath, and is suitable for clinical nursing of anorectal departments of all levels of medical institutions and patient family postoperative rehabilitation scenes.

The present invention discloses a binding protein that specifically binds to an AFP polypeptide and a tumor diagnostic kit, relating to the field of biotechnology. The binding protein can specifically bind to AFP and has good binding activity and affinity. Using the binding protein of the present invention to detect AFP can improve the sensitivity and specificity of AFP detection. The binding protein can be used for diagnosing or screening diseases that use AFP as a biomarker, and can be used to detect benign diseases that use AFP as a biomarker.

This invention discloses an exosome-based tumor diagnostic kit and its applications, relating to the fields of medical laboratory science and molecular diagnostics. The kit includes: exosome isolation components; exosome lysis and nucleic acid extraction components; internal standard and quantitative control components; reverse transcription components; molecular detection components; protein detection components; and interpretation and analysis components. This invention achieves complementary fusion of nucleic acid and protein information by simultaneously detecting exosome nucleic acid markers and exosome-derived protein markers from the same blood sample and employing a pre-defined normalization and weighted interpretation algorithm. This fusion strategy overcomes the problem of decreased sensitivity or specificity caused by biological heterogeneity or sample batch variations of single markers, making the identification of early or minor lesions more robust. Simultaneously, through synergistic interpretation among multiple markers, false positive signals originating from benign diseases or physiological fluctuations can be effectively suppressed, thereby improving the reliability of clinical screening and diagnosis.

The invention provides a metabolic marker combination for thyroid cancer diagnosis or auxiliary diagnosis and application of the metabolic marker combination, and belongs to the technical field of in-vitro diagnosis. According to the invention, phosphatidyl ethanolamine 36: 6e, erucic acid, triglyceride 58: 2, lysophosphatidylcholine 22: 5, cholic acid, L-glutamic acid and L-valyl-L-serine are combined to construct a diagnosis model for distinguishing healthy and benign thyroid diseases and thyroid cancer, and the diagnosis model has high diagnosis efficiency and clinical diagnosis significance. Besides, diagnosis models for distinguishing healthy diseases, thyroid benign diseases and thyroid cancer are respectively constructed for 9 metabolic markers and 11 metabolic markers comprising the metabolic marker combination, and the diagnosis models constructed by the 9 metabolic markers and the 11 metabolic markers are proved to have relatively high diagnosis efficiency; healthy and benign thyroid diseases and thyroid cancer can be effectively distinguished, and clinical diagnosis significance is achieved.

The invention discloses a biomarker for early diagnosis of pancreatic cancer and a detection kit, and belongs to the technical field of biological medicines. The invention discloses that a CpG dinucleotide methylation site in a CpG island of an MDGA2 gene promoter region can be used as a biomarker for early diagnosis of pancreatic cancer, the blank of relevance research of the MDGA2 gene and the pancreatic cancer in the prior art is filled, and the marker has extremely high specificity and sensitivity. The marker is targeted to SEQ ID NO.1. The specific CpG island of the MDGA2 gene shown in SEQ ID NO.1 is only in a remarkable high methylation state in pancreatic cancer tissue, the methylation level in normal pancreatic tissue is extremely low, the pancreatic cancer tissue and the normal pancreatic tissue can be effectively distinguished, meanwhile, the defects that a traditional serum marker is prone to being interfered by benign diseases and the false positive rate is high are overcome, and the application prospect is wide. And a brand new specific target is provided for early diagnosis of pancreatic cancer.

The invention provides a bladder cancer diagnostic kit based on a plurality of urine exosome lncRNAs (long non-coding ribonucleic acids). Experimental results show that the expression levels of the four lncRNAs (MALAT1, SCARNA10, LINC00963 and LINC01578) in the urine exosomes of bladder cancer patients are obviously higher than those of a healthy control group and a benign disease group. The lncRNA diagnosis combination shows excellent diagnosis efficiency (the sensitivity is 75.59%, the specificity is 84.37%, and AUC is equal to 0.862); after the kit is further combined with an existing bladder cancer marker NMP22, the diagnosis efficiency is remarkably improved (the sensitivity is 79.53%, the specificity is 87.50%, and AUC is equal to 0.900). Besides, the lncRNA combination has outstanding advantages on differential diagnosis of pathological high-grade bladder cancer, AUC reaches 0.917, and the limitation of accurate classification of bladder cancer in existing liquid biopsy is broken through.

The invention provides a metabolic marker composition for distinguishing kidney benign diseases and kidney cancer and application of the metabolic marker composition. Based on the metabonomics data of the plasma sample, the diagnosis model capable of distinguishing the kidney benign disease and the kidney cancer is constructed through a machine learning algorithm, and powerful support is provided for early noninvasive diagnosis and individualized treatment strategy formulation of the kidney cancer. The method is simple and convenient in sample collection, small in wound, high in sample stability and easy in standardized collection, is suitable for early screening and risk stratification of kidney diseases of a large scale of people, particularly provides an effective kidney cancer auxiliary diagnosis tool for areas with relatively deficient medical resources, and realizes accurate distinguishing of kidney benign diseases and kidney cancer.

The invention provides a plasma metabolism marker for kidney cancer diagnosis and application thereof, and belongs to the technical field of disease diagnosis. According to the invention, through comprehensive analysis and comparison of metabolic profiles of healthy people, kidney benign disease patients and kidney cancer patients, a group of metabolic marker combination with high specificity and significant difference is screened out, and the metabolic marker combination comprises 14 metabolic markers. As an end product of cell metabolic activity, the metabolic marker can more directly and sensitively reflect the abnormal metabolic state of tumor cells, so that early accurate recognition of kidney cancer and precancerous lesions is realized, the sensitivity of early diagnosis is remarkably improved, and the current clinical dilemma of'late stage once found 'is fundamentally reversed. The strategy is expected to greatly improve the survival rate and life quality of patients with kidney cancer, and a brand new path is provided for promoting precise medical treatment of kidney cancer.

The invention discloses a urine metabolism marker composition for diagnosing kidney cancer and application of the urine metabolism marker composition, and relates to the technical field of biomedicine. The urine metabolism marker composition for diagnosing the kidney cancer is prepared from aspartic acid, N, N-dimethylglycine and 7-methyluric acid. The urine metabolism marker composition provided by the invention has relatively high sensitivity and specificity and relatively high accuracy when being used for diagnosing kidney cancer. Meanwhile, when the urine metabolism marker composition is used for kidney cancer diagnosis, operation is easy, a sample is convenient to obtain, cost is low, non-invasive performance is achieved, and the urine metabolism marker composition is more suitable for large-scale crowd screening and regular tracking in areas with shortage of medical resources. Besides, by detecting the urine metabolism marker composition provided by the invention in a urine sample, whether a patient suffers from the kidney benign disease or the kidney cancer can be judged only through one-time detection, so that excessive examination of the patient suffering from the kidney benign disease can be avoided, excessive diagnosis and treatment can be reduced, and excessive panic of the patient can be avoided.

The utility model discloses a comprehensive device for perfusion and dispersion treatment of benign breast diseases, which comprises an electromagnetic pulse treatment device body, an infrared light breast cup, a thermal therapy breast cup, a breast perfusion device and an injection pump, and the released electromagnetic pulse is transmitted to the mammary gland through an electromagnetic pulse transmission device mounted on the electromagnetic pulse output end, so that the mammary gland is electromagnetically stimulated. According to the utility model, after the medicine is injected into the mammary gland through the injection equipment, the acupoints in the breast are stimulated to expand the catheter in the mammary gland through the effects of infrared light and electromagnetic pulse and the acupoints under the mammary gland of the human body and the theory of traditional Chinese medicine, so that the effect of dredging the mammary gland is achieved; therefore, the perfused medicine can be quickly dispersed into the whole breast, the effect of treating a lesion part in the breast by the medicine is achieved, and the treatment effect of a lesion body of the perfused medicine is better.

The present application relates to the technical field of medical examination, in particular to a nasopharyngeal carcinoma biomarker and application thereof. The present application finds that the overall antibody levels of BLRF2-IgA, BLRF2-IgG, BDLF1-IgA, BDLF1-IgG and BLLF3-IgA in serum of nasopharyngeal carcinoma patients are significantly higher than those of nasopharyngeal benign disease controls and healthy controls. Further analysis finds that the combination of the five antibodies can replace the combination of VCA-IgA antibody and EBNA1-IgA, and can be effectively used for the diagnosis of nasopharyngeal carcinoma, and can overcome the problems of strict biological safety conditions required in the production process of EBV-VCA natural protein and poor reagent stability between batches. In addition, the present application also finds that the greater the disease-free survival probability of nasopharyngeal carcinoma patients with low BLLF3-IgA and BDLF1-IgA antibody levels, which indicates the potential value of the two markers in the prognosis evaluation of nasopharyngeal carcinoma.